Fundraising FoxVital Venture Capital — 2018 Investments
1 investments dated 2018 · listed companies and verified rows first · show all
RubrYc Therapeuticsrubryc.cominApr 2018
Rubryc discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies for hard-to-drug targets.
AI & Machine LearningBiotechDeep TechSan Ramon, US
Paul Conley(Director)inBill Colston(Executive Officer, Director, Promoter)Jason Hong(Director)Isaac J. Bright(Executive Officer, Director)
Co-investorsThird Point VenturesPaladin Capital Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.